The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2024

Filed:

May. 01, 2019
Applicant:

Augusta University Research Institute, Inc., Augusta, GA (US);

Inventors:

Samir N. Khleif, Silver Spring, MD (US);

Vivek Verma, Augusta, GA (US);

Seema Gupta, Bethesda, MD (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/19 (2006.01); A61P 35/00 (2006.01); G01N 33/49 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); G01N 15/01 (2024.01); G01N 15/10 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 9/0019 (2013.01); A61K 38/195 (2013.01); A61P 35/00 (2018.01); G01N 33/4915 (2013.01); A61K 2039/80 (2018.08); A61K 45/06 (2013.01); G01N 15/01 (2024.01); G01N 2015/1006 (2013.01); G01N 2800/52 (2013.01);
Abstract

Compositions and methods of their use to detect and treat anti-PD1 therapy resistance are provided herein. Compositions that immunospecifically bind and deplete dysfunctional T cells are provided. The dysfunctional T cells that are depleted include CD38PD-1T cells, CD38CD8T-cells, or both. The dysfunctional T cells can be depleted, for example, by administering an antibody or fusion protein that specifically binds to dysfunctional T cells and promotes their depletion. In one embodiment the antibody is a bispecific antibody that can be specific for CD38 and CD8, or it can be specific for CD38 and PD-1. Also disclosed is a method of detecting and treating anti-PD1 therapy resistance by measuring the amount of CD38+PD1+CD8 T cells in blood or tissue samples obtained from a subject prior to anti-PD1 therapy and administering an anti-CD38/CD8 or anti-CD38/PD-1 depleting/blocking antibody to the subject prior to anti-PD1 therapy.


Find Patent Forward Citations

Loading…